Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

OBJECTIVE: To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). METHODS: In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg o...

Descripción completa

Detalles Bibliográficos
Autores principales: Edan, G, Kappos, L, Montalbán, X, Polman, C H, Freedman, M S, Hartung, H-P, Miller, D, Barkhof, F, Herrmann, J, Lanius, V, Stemper, B, Pohl, C, Sandbrink, R, Pleimes, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215285/
https://www.ncbi.nlm.nih.gov/pubmed/24218527
http://dx.doi.org/10.1136/jnnp-2013-306222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215285/
https://www.ncbi.nlm.nih.gov/pubmed/24218527
http://dx.doi.org/10.1136/jnnp-2013-306222

Ejemplares similares